|03/17/14||Kips Bay Medical Announces FDA Approval for U.S. Expansion of Its eMESH I Clincal Feasibility Study|
|MINNEAPOLIS, March 17, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS) along with Manny Villafaña, its Founder, Chairman and CEO, announced today that the United States Food & Drug Administration ("FDA") has granted an approval for Kips Bay Medical to include more U.S. patients and U.S. study sites in its "eMESH I" clinical feasibility trial of its eSVS® Mesh.
In its initial approval, the FDA indicated that it would allow a staged enrollment within the United States, starti... |
|03/12/14||Kips Bay Medical Provides Business Update and Reports Fourth Quarter and Full Year 2013 Results|
|MINNEAPOLIS, March 12, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, eSVS® Mesh, for use in coronary artery bypass grafting surgery, today provided a business update and announced financial results for its fourth quarter and full year ended December 31, 2013.
Enrollments and site activations continue in the Kips Bay eMESH I clinical feasibility... |
|02/10/14||Kips Bay Medical Announces the First Austrian Implant of the eSVS Mesh|
|MINNEAPOLIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- Manny Villafaña, Chairman and CEO of Kips Bay Medical Inc. (Nasdaq:KIPS), announced that on January 14, 2014, the first commercial implant of the Company's eSVS® Mesh in Austria was performed at the Medical University of Vienna in Vienna, Austria. This implant was performed under the direction of Professor Dr. Günther Laufer. The presiding surgeon in the case, Professor Dr. Sigrid Sandner, commented that the eSVS Mesh was easily deployed with no com... |
|01/29/14||Kips Bay Medical Announces Closing of Public Offering of Common Stock, Including Exercise of Underwriters' Over-Allotment Option|
|MINNEAPOLIS, Jan. 29, 2014 (GLOBE NEWSWIRE) -- Kips Bay Medical, Inc. (Nasdaq:KIPS), a medical device company focused on manufacturing and commercializing its external saphenous vein support technology, the eSVS® Mesh, for use in coronary artery bypass grafting surgery, today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and the sale of an additional 785,000 shares of common stock pursuant to the exercise in full by the underwr... |